Navigation Links
New paper sheds light on bacterial cell wall recycling
Date:9/8/2008

A new paper by a team of researchers led by Shahriar Mobashery, Navari Family Professor of Life Sciences at the University of Notre Dame, provides important new insights into the process by which bacteria recycle their cell wall.

The cell wall is a critically important entity for bacteria and essential for their survival. It is a rigid entity encasing the bacterium, and antibiotics are designed to interfere with disease processes by affecting its maturation. The function of antibiotics is to impair the cell wall, leading to bacterial death.

Scientists have determined that during bacterial growth a substantial amount of the parental cell wall is recycled. Although the recycling process has been known, its intricacies have not been well understood to date.

Mobashery's team synthesized pieces of the cell wall of the bacterium Escherichia coli in his laboratory and was able to use the synthetic wall components to observe the chemical reactions that take place during the recycling process.

The researchers found that a member of the lytic transglycosylases family of enzymes known as M1tB performed the requisite cell wall fragmentation on the synthetic sample of the cell wall from their laboratory. They also were able to measure the rate of the transformation by M1tB, determining that 14,000 pieces of the cell wall are processed by each molecule of M1tB in one bacterial generation.

The product of the M1tB reaction on the cell wall is the entity that initiates the recycling event, but when it diffuses out of the bacterium, it causes the onset of the pro-inflammatory events associated with bacterial infections.


'/>"/>

Contact: Shahriar Mobashery
mobashery@nd.edu
574-631-2933
University of Notre Dame
Source:Eurekalert

Page: 1

Related biology news :

1. Beyond batteries: Storing power in a sheet of paper
2. Coal and black liquor can produce energy from papermaking
3. New paper examines dams effects on California salmon
4. 454 Sequencing: Science paper describes a novel, highly efficient method of sequencing ancient DNA
5. RAND paper finds diesel, hybrid vehicles can provide more societal benefits than gas-powered autos
6. Experts from Stevens, Merck, publish joint paper, Biosynthetic Studies of Platensimycin
7. New whitepaper offers options for university implementation of NIH policy
8. For the paper trail of life on Mars or other planets, find cellulose
9. Nature paper describes technique for extracting hierarchical structure of networks
10. A gentle touch for better control, a quantum mechanical con, and milestone PRL papers
11. U.S. IEEE members to report on Sci-Tech at California newspapers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... person takes a pill full of a potent and effective drug, ... where it is needed a waste of money and inconvenient ... is a treatment for a serious illness. Polymer chemists ... up to design a solution. Their research to identify, understand, ...
... 2011 Fukushima nuclear plant disaster will reach the shores of ... incident but is likely to be harmless according to new ... atmospheric radiation was detected on the US west coast within ... plume take considerably longer to travel the same distance., In ...
... MD. AUGUST 28, 2013A competition for a $5,000 prize ... member of the American Society for Cell Biology (ASCB) ... The ASCB Kaluza Prize supported by Beckman Coulter, Inc., ... German mathematician Theodor Kaluza (1885-1954), who is the namesake ...
Cached Biology News:Researchers develop novel polymer to help oral medications reach the bloodstream 2Researchers develop novel polymer to help oral medications reach the bloodstream 3Researchers develop novel polymer to help oral medications reach the bloodstream 4Researchers develop novel polymer to help oral medications reach the bloodstream 5Fukushima radioactive plume to reach US in 3 years 2New ASCB Kaluza Prize recognizes graduate student research 2
(Date:5/6/2015)... 2015 Histogen, Inc., a regenerative ... of cells grown under simulated embryonic conditions, will ... candidate for melanoma during the 2015 Society of ... 6-9, 2015 in Atlanta, GA. , Histogen has ... soluble material with anti-oncologic properties, with potential benefit ...
(Date:5/6/2015)... The Remedy Group , the ... the specialty pharmacy industry, will be exhibiting, presenting, and ... Pharmacy Summit. The Summit will be held May 4-8, ... is the largest annual gathering for the specialty pharmacy ... pharmacy providers, pharma/biotech manufacturers, and payers, to learn more ...
(Date:5/5/2015)... Mass. , May 5, 2015  Blueprint ... closing of its initial public offering of 9,367,708 ... price of $18.00 per share, including shares of ... the underwriters of their option to purchase additional ... offering to Blueprint Medicines were approximately $168.6 million, before ...
(Date:5/5/2015)... Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... the detection of foodborne pathogens,  today announced that Paul ... Merrill Lynch 2015 Health Care Conference on May 12 at ... the Wynn, Las Vegas NV. ... available through the investor relations section of Roka Bioscience,s website ...
Breaking Biology Technology:Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2Blueprint Medicines Announces Closing of Initial Public Offering 2
... Laboratories,Inc., a global provider of medical, nutraceutical, consumer ... a letter from The,Nasdaq Stock Market informing the ... of the Company, and would suspend trading in ... business on Thursday, August,16, 2007. As previously ...
... in Number and Viability of Stem Cells Derived from ... BioLife,s Patented Preservation Media, BOTHELL, Wash., Aug. 17 ... developer and marketer of,proprietary hypothermic storage and cryopreservation media ... as the exclusive,supplier of preservation media to the New ...
... Mass., Aug. 17 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... approvable letter from the U.S. Food and Drug ... valrubicin for intravesical,instillation, is the only product approved ... carcinoma in situ (CIS) of the,urinary bladder. ...
Cached Biology Technology:Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets 2BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc. 2BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc. 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4